$--
(Market cap
$18 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
3.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
3,061,690
10 Years Aggregate
CFO
$-164.57 Mln
EBITDA
$-172.82 Mln
Net Profit
$-178.33 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aeterna Zentaris - ADR
| 115.1 | -24.6 | -48.7 | 52.7 | -39.7 | -38.3 | -49.2 |
|
BSE Sensex*
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Aeterna Zentaris - ADR
| -41.5 | -64.7 | -15.4 | -53.2 | -69.0 | 24.4 | -34.4 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Aeterna Zentaris - ADR
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is... Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. Read more
-
President, CEO & Executive Director
Dr. Klaus Paulini Ph.D.
-
President, CEO & Executive Director
Dr. Klaus Paulini Ph.D.
-
Headquarters
Toronto
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aeterna Zentaris - ADR
What is the current share price of Aeterna Zentaris Inc - ADR Today?
The share price of Aeterna Zentaris Inc - ADR is $4.00 (NASDAQ) as of 06-Sep-2024 09:30 EDT. Aeterna Zentaris Inc - ADR has given a return of -39.65% in the last 3 years.
What is the current PB & PE ratio of Aeterna Zentaris Inc - ADR?
Since, TTM earnings of Aeterna Zentaris Inc - ADR is negative, P/E ratio is not available.
The P/B ratio of Aeterna Zentaris Inc - ADR is 0.48 times as on 06-Sep-2024, a 84 discount to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Aeterna Zentaris Inc - ADR?
The 52-week high and low of Aeterna Zentaris Inc - ADR are Rs -- and Rs -- as of 04-Sep-2026.
What is the market cap of Aeterna Zentaris Inc - ADR?
Aeterna Zentaris Inc - ADR has a market capitalisation of $ 18 Mln as on 06-Sep-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Aeterna Zentaris Inc - ADR?
Before investing in Aeterna Zentaris Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.